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ABSTRACT  
Background 
The first rate-limiting step for primary indicated prevention of psychosis is the 
detection of young people who may be at risk. The ability of specialised clinics 
to detect individuals at risk for psychosis is limited. A clinically based, 
individualised, transdiagnostic risk calculator has been developed and 
externally validated to improve the detection of individuals at risk in secondary 
mental health care. This calculator employs core sociodemographic and clinical 
predictors, including age, which is defined in linear terms. Recent evidence has 
suggested a non-linear impact of age on the probability of psychosis onset.  
Aim 
To define at a meta-analytical level the function linking age and probability of 
psychosis onset. To incorporate this function in a refined version of the 
transdiagnostic risk calculator and to test its prognostic performance, compared 
to the original specification. 
Design 
Secondary analyses on a previously published meta-analysis and clinical 
register-based cohort study based on 2008-2015 routine secondary mental 
health care in South-London and Maudsley (SLaM) National Health Service 
(NHS) Foundation Trust. 
Participants 
All patients receiving a first index diagnosis of non-organic/non-psychotic 
mental disorder within SLaM NHS Trust in the period 2008-2015.  
Main outcome measure 
Prognostic accuracy (Harrell’s C).  
Results 
91199 patients receiving a first index diagnosis of non-organic and non-
psychotic mental disorder within SLaM NHS Trust were included in the 
derivation (33820) or external validation (54716) datasets. The mean follow-up 
was 1588 days. The meta-analytical estimates showed that a second-degree 
fractional polynomial model with power (-2, -1: age1=age-2 and age2=age-1) 
was the best fitting model (P<0.001). The refined model which included this 
function showed an excellent prognostic accuracy in the external validation 
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(Harrell’s C 0.805, 95%CI from 0.790 to 0.819), which was statistically higher 
than the original model, although of modest magnitude (Harrell’s C 
change=0.0136, 95%Cis from 0.006 to 0.021, P<0.001). 
 
Conclusions 
The use of a refined version of the clinically based, individualised, 
transdiagnostic risk calculator, which allows for non-linearity in the association 
between age and risk of psychosis onset may offer a modestly improved 
prognostic performance. This calculator may be particularly useful in young 
individuals at risk of developing psychosis who access secondary mental health 
care.  
 
KEYWORDS: Psychosis, schizophrenia, at risk, CHR, transdiagnostic 
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INTRODUCTION 
Primary indicated prevention in individuals meeting a Clinical High Risk state 
for Psychosis (CHR-P1) entails three stepped core components: efficient 
detection of individuals at risk, an accurate prognosis of outcomes and an 
effective preventive treatment that can impact the course of the disorder (Figure 
1)2.  
 
The first rate-limiting step is the detection of children, adolescents and young 
adults aged 8-403 (more frequently 14-35)4 who may be at risk of developing 
psychosis. Their detection is based on recruitment campaigns5 that filter 
individuals who have accumulated several risk factors6 for the development of 
psychosis, thus enriching the level of risk. The actual ability of specialised CHR-
P clinics4 to detect individuals at risk for psychosis is limited. The first study to 
explore this issue has estimated that only about 5% of individuals who will later 
develop a first episode of psychosis in secondary mental health care was 
detected by the local CHR-P specialised clinics at the time of their CHR-P 
stage7,8. Even front-line youth mental health services can detect only about 
12% of first episodes case9. It is therefore clear that we need to improve our 
ability to detect CHR-P individuals in secondary mental health, primary care 
and the community. To overcome this substantial challenge, a clinically based, 
individualised, transdiagnostic risk calculator has been developed and 
externally validated twice7,10,11. This calculator leverages electronic health 
records to screen secondary mental health care trusts at scale. Secondary 
mental healthcare is characterised by an incidence of psychosis of 3% at 6-
year, which is higher than the risk of psychosis of 0.62 at 6-year in the local 
general population (see eFigure 1 published in7). The calculator uses as key 
predictors ICD-10 index diagnosis (because it allows several diagnostic spectra 
it is termed as transdiagnostic -see12), age, gender, age by gender and 
ethnicity, which have been selected on the basis of a priori clinical knowledge 
13,14.  
 
Specifically, age has been included because it is one of the most established 
sociodemographic risk factor for psychosis15. In the original version of the 
transdiagnostic risk calculator, the impact of age on the risk of psychosis onset 
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has been defined in linear terms. However, converging evidence from 
independent meta-analyses15,16 suggests that age may exert a non-linear effect 
on the risk to psychosis onset. For example, a recent umbrella review17 found 
that the risk for psychosis increases from childhood to young adulthood, to peak 
within 15-35 years16, and then declines after this age, independent of gender 
(age older than 35 was found to be a protective factor)16. It is thus possible that 
the use of non-linear definitions of age would better represent the impact of this 
factor on the onset of psychosis, in particular for the youngest CHR-P groups18.  
 
In this study, we test such a hypothesis. We first employ independent meta-
analytical data to investigate the epidemiological association with age and risk 
of developing psychosis onset in the general population. We then use this 
information to refine the original transdiagnostic risk calculator and to test 
whether its prognostic accuracy would improve. The results of this study can 
inform future risk prediction research in the field of early psychosis.  
 
METHODS 
 
Data source 
South-London and the Maudsley (SLaM) is a National Health Service (NHS) 
mental health Trust. SLaM provides secondary mental health care to a 
population of approximately 1.3 million residents of four London boroughs 
(Lambeth, Southwark, Lewisham and Croydon). The Trust is effectively 
digitalised and paper-free,19 and all patients have a personal electronic clinical 
record. It is a legal requirement for SLaM healthcare professionals to keep 
these records up to date.19 The SLaM register contains the full clinical records 
of all patients, which are continually updated throughout their care, regardless 
of discharges from and or referrals to other services. A Clinical Record 
Interactive Search (CRIS) tool19 was implemented to facilitate searching and 
retrieval of full but anonymised clinical information for research purposes.19 
Because the CRIS tool draws directly from these electronic health records, it 
provides valuable ‘real-world’ and ‘real-time’ information on routine mental 
health care.20 CRIS has already been used in At Risk Mental State (ARMS) 
studies21 as well as in over 70 previous publications.22-24 CRIS-related methods 
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and descriptive data of the SLaM cohort have been extensively detailed. 19,20,25-
28 
 
Study population 
As indicated in the original study as in its replication10,29, all individuals 
accessing SLaM services in the period 1st January 2008 to 31st December 2015, 
and who received a first index primary diagnosis of any non-organic and non-
psychotic mental disorder, were initially considered eligible. We then excluded 
those who developed psychosis in the three months immediately following the 
first index diagnosis. Approval for the study was granted by the Oxfordshire 
Research Ethics Committee C. Because the data set was made up of de-
identified data, informed consent was not required19. 
 
Variable definitions 
The outcome (risk of developing any psychotic disorder), predictors, and time 
to event were automatically extracted using CRIS.19 Predictors (index 
diagnosis, age, gender, ethnicity, and age by gender interaction) were 
preselected on the basis of previous meta-analytical clinical knowledge, as 
recommended30 (see the original study for full details7). Age was entered as a 
continuous predictor and measured at the time of the index diagnosis, while 
self-assigned ethnicity and index diagnoses were operationalised as previously 
indicated11. The outcome (risk of developing any psychotic disorder) was 
defined as the emergence of the first ICD-1031 primary diagnosis of non-organic 
psychotic disorder, occurring at least three months after the index diagnosis as 
recorded in the local electronic medical records: schizophrenia spectrum 
psychoses (schizophrenia [F20.x, except F20.4/F20.5], schizoaffective 
disorder [F25.x], delusional disorders [F22.x, F24], acute and transient 
psychotic disorders [F23.x]), unspecified nonorganic psychosis (F28/F29), 
psychotic disorders due to psychoactive substance use ([F10-F19].5), and 
affective psychoses (mania with psychotic symptoms [F30.2], bipolar affective 
disorder with psychotic symptoms [F31.2, F31.5], and depression with 
psychotic symptoms [F32.3/F33.3]). Accordingly, baseline ICD-10 psychotic 
disorders were excluded, with the exception of Acute and Transient Psychotic 
Disorders (F23.x), which are, by definition, clinically remitting and non-
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psychotic within three months (short-lived). The rationale for including the 
ATPD is due to the fact that this group is prognostically similar to the Brief 
Limited Intermittent Psychotic Symptom (BLIPS) or Brief Limited Psychotic 
Symptoms (BIPS) subgroups of the CHR-P construct (for details on these 
competing operationalisation see previous publications on the diagnostic and 
prognostic significance of BLIPS32,33). On a diagnostic level, about two thirds 
(68%) of BLIPS meet ATPD criteria 32. Individuals with ATPDs/BLIPS are also 
those more likely to present unmet clinical needs because they are too ill for 
CHR-P services and not enough ill for first episode services34,35. 
 
The follow-up (time to event) began three months after the date of the index 
diagnosis within SLaM, censored at 1st April 2016. This lag period was chosen 
to allow patients sufficient time after their index diagnosis to meet the ICD-10 
duration criterion ATPD. 
 
Statistical analysis  
This original clinical register-based cohort study was conducted according to 
the REporting of studies Conducted using Observational Routinely-collected 
health Data (RECORD) Statement36.  
 
Development and validation databases 
The same development and validation databases were used in the current 
study. Because of significant sociodemographic differences between the SLaM 
boroughs (from20: see Table 1 and Figures 2 and 3), we used nonrandom split-
sample approach using the geographical location to define the development 
and external validation,37 with the Lambeth and Southwark cases in the 
derivation sample and all other cases in the validation sample. The use of non-
random split based on geographical location was based on the substantial 
sociodemographic differences across these urban areas19, which can optimise 
the estimation of external prognostic accuracy13. Model development and 
validation followed the guidelines of Royston et al.,38 Steyerberg et al.39 and the 
Transparent Reporting of a multivariable prediction model for Individual 
Prognosis Or Diagnosis (TRIPOD).37  
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Several steps were followed to explore similarities and differences between the 
derivation and validation dataset. Firs, sociodemographic characteristics were 
compared. Second, the cumulative incidence of psychosis across the two 
databases was estimated with the Kaplan-Meier failure function (1-survival) and 
Greenwood 95% CIs40. Then we visually compared the two Kaplan-Meier 
failure functions. If the visual inspection of the curves reveal that they vary 
noticeably or if there are differences in their shapes, systematic differences 
within the study populations may be indicated41. Third, we also reported the 
spread (SD) and the mean of the prognostic index of the original model in the 
two databases. An increased (or decreased) variability of the prognostic index 
would indicate more (or less) heterogeneity of case-mix between the two 
databases, and therefore, of their overarching target populations42. Differences 
in the mean prognostic index indicate differences in overall (predicted) outcome 
frequency, reflecting case-mix severity between the two databases (and 
revealing the model’s calibration-in-the-large in the validation database)42. 
 
Development of the revised model  
In line with the rationale detailed in the introduction, we tested here a refined 
version of the original model. While in the original model age was entered as a 
continuous predictor, we employed here a revised model which additionally 
allowed for non-linearity in the association between age and risk of psychosis. 
All of the other predictions remained unchanged.  
First, the type of non-linear function linking age and risk of psychosis was 
defined a priori on the basis of independent data not based on the current 
derivation dataset. We used a robust systematic review and meta-analysis 
reporting on the incidence of any psychotic disorders in England15,43. Using a 
priori knowledge to build prognostic model is a robust and recommended 
approach, which can minimise the risk of overfitting13. Overfitting would be high 
if we would have used the same dataset to estimate the type of non-linear 
function linking age and risk of psychosis, and then fitted a prognostic model 
on the same data13. Therefore, we extracted Figure 4.4 from the previously 
published meta-analysis, which was reporting the meta-analytical incidence of 
all clinically relevant psychoses by age and gender, reported in43. This figure 
represents the most updated and largest epidemiological estimate of the 
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incidence of psychotic disorders in England. The figure was then digitalised into 
a.png picture file so that each curve angle or could be identified by its pixel 
coordinate. A free image manipulation software DigitizeIt software 
(http://www.digitizeit.de/) was then used to identify the pixel coordinates for 
each curve. The meta-analytical data thus extracted were imported into an 
electronic dataset and age ranges were remapped to a linear (ordinal) variable. 
We then applied a fractional polynomial (FP) approach to identify the best non-
linear model fitting the observed outcomes. Although there are alternative 
modelling strategies to deal with non-linear effects such as quadratic regression 
and spline-based models, FP is probably the most powerful statistical method 
to capture the non-linear effect of variables44,45. FP of degree m for the variable 
X with powers p1…pm is given by FPm(X)= β1Xp1+….βmXpm (for simplicity, we 
suppress the constant term, β0). Usually m=1 or m=2 is sufficient for a good fit. 
Therefore there are two classes of FP: first-degree fractional polynomials 
(FP1), and second-degree fractional polynomial (FP2)46. Powers p1 and p2 are 
taken from a special set S = {–2, –1, –0.5, 0, 0.5, 1, 2, 3}44. Thus, the first-
degree polynomial models (FP1) is β1Xp1, and perform 8 tests, detects whether 
the fit is improved by a power transformation of the variable X in Xp. FP with a 
value of p = 1 indicates a linear regression while p = 0 indicates that a 
logarithmic transformation is required for optimum linear modelling of the 
variable X. The second-degree polynomial models (FP2) are an extension 
to β1Xp1 + β2Xp2 which compares 36 different power combinations. The case of 
(p1 = 1, p2 = 2) is equivalent to quadratic regression. The case p1 = p2 is known 
as repeated power model and has been defined as β1Xp+ β2XpLn X 45.  
The STATA package “fp” was then used to isolate the FP powers that were 
best fitting the meta-analytical data and thus representing the epidemiological 
impact of age on the risk of psychosis.  
The package fp performs FP comparisons across the powers (-2 -1 -.5 0.5 1 2 
3) and two degrees. Therefore, the linear predictor is included in the 
comparisons. Different FP models are compared and the corresponding model 
deviance, defined as twice the negative log-likelihood, is estimated. Under 
linear regression, a partial F test comparing the model is performed and a X2 
statistic is computed and we selected the best fitting model as the model with 
the lowest deviance. Overall, this approach delivered an epidemiological 
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estimate of the relationship between age and psychosis, at meta-analytical 
level. In a subsequent step, we tested the real-world benefit of the specific 
revised model. To further illustrate the type of FP that was selected through this 
method, we plotted the FP function that was fitted to the epidemiological meta-
analytical data and reported its regression coefficients. However, as indicated 
above, our aim was to use a priori knowledge to identify the type of fractional 
polynomial function and not specifically the regression coefficients of the FP. 
We then used Cox proportional hazards multivariable complete-case analyses 
to evaluate the effects of the revised model on the development of non-organic 
ICD-10 psychotic disorders and time to development of psychosis, after 
checking the proportional hazards assumption.47 This model with all 
preselected predictors was first fitted to the derivation data to estimate the 
optimal regression coefficients. Performance diagnostics of individual predictor 
variables in the derivation dataset were explored with Harrell’s C index,38 which 
is similar to the area under the receiver operating characteristic curve. Values 
of 0.9-1.0 are considered outstanding, 0.8-0.9 excellent and 0.7-0.8 
acceptable48. We then generated individual prognostic scores, allowing a 
prognostic index for risk of psychosis onset to be developed in the derivation 
dataset.49 
 
External validation of the revised model 
The regression coefficients as estimated in the derivation dataset were then 
applied to each case in the external validation dataset, to generate the PI in the 
validation dataset. Overall model performance (the distance between the 
predicted outcome and actual outcome39) was assessed with the Brier score 
(the average mean squared difference between predicted probabilities and 
actual outcomes, which also captures calibration and discrimination aspects39). 
A lower score indicates higher precision and less bias, but interpretation 
depends on the incidence of the outcome.39 Overall performance was further 
investigated with Royston’s modification of Nagelkerke’s R2 (indexing the 
proportion of variation explained by the model through the str2d STATA 
package).50 Calibration (the agreement between observed outcomes and 
predictions39) was assessed with the regression slope of PI39 (which also 
captures discrimination and model fit),38 and with the calibration-in-the-large39.  
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Discrimination (accurate predictions discriminate between those with and those 
without the outcome39) was addressed with Harrell’s C index (primary 
prognostic accuracy outcome)38 and with the discrimination slope (difference in 
mean of predictions between outcomes39). 
To test whether the refined model was associated with improved performance 
compared to the original model, Harrell’s C index was compared across the two 
models in the validation dataset, using the “lincom” function as detailed in an 
established procedure51. Recent studies indicate that unbiased and precise 
estimation of performance measures can be achieved with a minimum of 100 
events in the external validation dataset.52  
 
All analyses were conducted in STATA 14. 
 
RESULTS  
Sociodemographic and clinical characteristics of the derivation and 
validation datasets 
As indicated in the original study7, of 92227 patients receiving a first index 
diagnosis of non-organic and non-psychotic mental disorder within SLaM in the 
period 2008-2015, 91199 fulfilled the study inclusion criteria and were included 
in the derivation or validation datasets. The mean follow-up was 1588 days 
(95% CI 1582-1595) with no differences between the derivation and validation 
datasets. The core characteristics of the sample are presented in Table 1. The 
cumulative incidence across the derivation and validation datasets is 
represented in Figure 2 and indicates a lower risk of psychosis in the validation 
dataset compared to the derivation dataset. The mean values of the prognostic 
index were -1.32 (SD 0.896) in the derivation dataset and -1.581 (SD 0.888) in 
the validation dataset, indicating a slightly reduced variation in the validation 
dataset and some case-mix.  
 
*** FIGURE 2 ABOUT HERE *** 
*** TABLE 1 ABOUT HERE *** 
 
Model development 
Fractional polynomial analysis 
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The fractional polynomial analysis in the independent meta-analytical data 
confirmed that a second-degree fractional polynomial (FP2) model with power 
(-2, -1) was the best fitting model minimising the deviance (deviance=545.188, 
SD=20.14, F=33.55, P<0.001, Figure 3). A second-degree (FP2) model with 
power (-2, -1) was fitting better the meta-analytical data compared to the linear 
model (FP1: age1=age-1 deviance=552.066, SD=21.10) which was used the 
original prognostic model7, to a first degree (FP1) with power 0.5 (age1=age0.5, 
deviance=551.33, SD=20.982) and to the omission of this predictor 
(deviance=592.276, SD=29.951). Accordingly, we generated two (unscaled) 
variables: age1=age-2 and age2=age-1. The resulting non-linear meta-analytical 
polynomial function is depicted in Figure 3. The fitted function in Figure 3 was 
incidence of any psychotic disorders per 100,000 person-year = -11.27-
206.35*age-2+281.75*age-1. 
 
*** FIGURE 3 ABOUT HERE *** 
 
Model performance in the derivation dataset 
In the derivation dataset, there were 1001 transitions to psychosis. The 
multivariable model significantly predicted psychosis onset (likelihood ratio chi-
square test=1878, p<0.001, Table 2).  
 
*** TABLE 2 ABOUT HERE *** 
 
Beyond the age effect, there were no substantial changes in the significance of 
the predictors compared to the original model: male gender (relative to females), 
Black, Asian, mixed, and other ethnicities (relative to White ethnicity) remained 
significantly associated with an increased risk of psychosis (Table 2). Across 
males, the risk of psychosis remained negatively associated with increasing 
age (Table 2). Since the age by gender interaction was included in the model, 
age was also retained as a linear predictor, which was not more significant. 
Compared with the reference CHR-P designation, all of the other ICD-10 
mental disorders were still associated with a lower risk of developing psychosis 
(Table 2). The exceptions were bipolar mood disorders and acute and transient 
psychotic disorders that showed a comparable and higher risk of psychosis 
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than the CHR-P, respectively (Table 2). Model diagnostics using the C index 
are detailed in Table 2. The model showed excellent overall apparent 
performance (excellent discrimination, C index 0.814) and explained 
approximately 77% of the observed variation (Table 3).  
 
*** TABLE 3 ABOUT HERE *** 
 
Compared to the original model, the refined model was associated with a 
modest (Harrell’s C change=0.014) but significant (95%CI from 0.008 to 0.020, 
t=4.63, P<0.001, Table 3) improvement in performance.  
 
Model performance in the validation dataset 
In the validation dataset, the refined model was associated with a relatively 
lower Harrell’s C (and explained 74% of the observed variation) which however 
remained excellent: 0.805 (95%CI from 0.790 to 0.819). This was likely due to 
the lower risk of psychosis and reduced variation in the validation database. 
However, the refined model was still characterised by a modest (Harrell’s C 
change=0.0136) and significant (95%Cis from 0.006 to 0.021, t=3.56, P<0.001) 
improvement in performance, compared to the original model.  
 
DISCUSSION  
This study advances knowledge in the field of the detection of individuals at risk 
for psychosis using automated methods that employ electronic health records. 
Meta-analytical FP analyses demonstrated that age has a non-linear effect on 
the risk of psychosis onset. This evidence was used to refine a previously 
validated individualised clinically based, transdiagnostic risk calculator. The 
refined model demonstrated modest but significantly superior prognostic 
accuracy than the original model in the external validation.  
 
The core aim of this study was to refine an automated detection tool to identify 
individuals at risk of developing psychosis at scale. Overall, the improved 
prognostic accuracy was modest in magnitude, although statistically significant. 
Because of the limited size of the improvement, it is unlikely it will be associated 
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with substantially higher clinical benefits. Yet, medical knowledge proceeds by 
incremental steps that can eventually deliver substantial advancements. In this 
light, methodological guidelines recommended updating and refining the 
existing prognostic models through several iterations, rather than dropping the 
model and develop new ones from scratch13. In fact, the current refined version 
of this prognostic model may show higher prognostic stability in other clinical 
scenarios, for example, in young CHR-P populations aged 16-20. In fact, as 
indicated in Figure 3, the polynomial function may show a better fitting than the 
linear function in this specific age period. Improving the prognostic accuracy of 
clinical outcomes in young CHR-P population is particularly important because 
current CHR-P psychometric interviews do not perform well in these patients. 
Accumulating evidence has demonstrated a dilution of transition risk in 
underage CHR-P patients compared to older CHR-P samples18. This effect 
may cause instability in prognostic models and lack of generalisability. 
Conversely, the current refined prognostic model may be more flexible and, by 
capturing non-linear as well as linear effects of age in the youngest groups, 
may be more generalisable across different age groups. Notably, the original 
prognostic model was not only transdiagnostic but also ageless. As such, it has 
the potential to be applied to individuals at risk of psychosis over the 
neurodevelopmental period, provided they have received an initial ICD-10 
diagnosis while accessing secondary mental health care. Because of this 
characteristic, the refinement of the current model to incorporate 
epidemiological effects of age may be associated with some pragmatic utility. 
Clearly, this would need to be demonstrated in future cohort studies of young 
CHR-P samples. These results may also have other relevant impacts. 
 
On a conceptual level, improved detection of individuals at risk for psychosis is 
urgently needed because, as detailed in the introduction, current detection 
strategies are highly inefficient. More to this point, it is also essential to 
standardise the way individuals at risk for psychosis are recruited for 
undergoing a CHR-P assessment. In fact, individuals meeting CHR-P criteria 
display functional impairments53 and a 20% risk of developing psychosis at 2-
year54 (but not an increased risk of developing other non-psychotic mental 
disorders55,56). The meta-analytical prognostic accuracy of the CHR-P 
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instruments is excellent (Area Under the Curve, AUC at 3-year: 0.9) and is 
comparable to that of other preventive paradigms in organic medicine57. Yet, 
such an excellent prognostic accuracy is mostly due to CHR-P instruments’ 
ability to rule out a state of risk for psychosis. In fact, testing negative at a CHR-
P assessment leads to a 10-fold decrease in the (posttest58) risk of developing 
psychosis, (negative likelihood ratio of 0.01)57,58. Conversely, the CHR-P 
instruments’ ability to rule-in a state of risk for psychosis is modest. In fact, 
testing positive a CHR-P assessment leads only to a 1.8-fold increase in the 
(posttest58) risk of developing psychosis (positive likelihood ratio of 1.8)57,58. 
The consequence is that CHR-P instruments’ prognostic accuracy is excellent 
provided samples to which they are applied undergo some risk enrichment 
before the assessment (termed as pretest level of risk58). In fact, CHR-P 
instruments do not work well when they are applied outside clinical samples 
that had already undergone some pretest risk enrichment59,60. This is 
traditionally obtained during the recruitment or detection phase, which is mostly 
unstandardised. For example, when individuals are recruited from mental 
health services, they accumulate several risk factors for psychosis6 and their 
level of risk raises to 15% at 3-years worldwide5. Such a pretest level of risk for 
psychosis is substantially higher compared to the 0.43% 3-year risk of the local 
age-matched general population14,61. These considerations explain the most 
important challenges of the CHR-P paradigm. For example, the lack of 
statistical power because of the poor level of psychosis risk led to 
underpowered and negative randomised controlled trials in this population62. 
Furthermore, small sample sizes in CHR-P trials are associated with inaccurate 
estimates and large 95% confidence intervals that have been recently observed 
in meta-analyses of CHR-P treatments63. The main problem is that it is currently 
not possible to control recruitment strategies in a systematic fashion. For 
example, owing to intense outreach campaigns in the community, the actual 
posttest risk of psychosis in CHR-P samples has been declining from 29% 
(201264) to 20% (201654) worldwide. There are however some exceptions to 
this phenomenon. For example, in the Outreach and Support in South-London 
CHR-P service4 transition risk has not been declining over time. This is due to 
the fact that recruitment strategies have overall maintained a stable pretest risk 
enrichment65. These points altogether corroborate the scientific rationale for 
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developing innovative detection and recruitment strategies that could 
guarantee a clinically meaningful level of pretest risk enrichment in this field.  
 
On an empirical level, this study has some additional impact on the field of 
prognostic modelling for early psychosis. First, to our best knowledge our 
approach is the first one to date which has ever attempted to estimate the age 
effect on the probability of psychosis onset at meta-analytical level. Because 
this finding is per se robust, future prognostic modelling studies in the field of 
early psychosis that are considering using age as a predictor could further 
consider defining it in polynomial terms (age1=age-2 and age2=age-1), as 
proposed here. Importantly, in our model age was also retained as a linear 
predictor because the age by gender interaction was included in the model. 
Second, there are some practical implications relating to the real-world 
implementation of the individualised transdiagnostic risk calculator. A feasibility 
implementation study is ongoing in South-London and could consider using the 
refined version of the calculator11. The refinement of prognostic models and 
their updating to facilitate their real-world clinical usage is a recommended 
procedure to improve their prognostic performance as opposed to continuously 
developing new models that eventually do not enter in clinical routine13 
 
Limitations of this study are mostly inherited from the original model and are 
fully detailed in the previous publications7,29. In brief, our diagnoses have high 
ecological but unclear psychometric validity. As such it is possible that the 
model is charting out relationships that reflect diagnostic practice within the 
United Kingdom. Future external replication studies are needed to establish the 
generalizability of this model outside the UK. Randomised clinical trials or 
economic modelling are needed to assess whether our risk calculator 
effectively improves patient outcomes. 
 
CONCLUSIONS 
The use of a refined version of the clinically based, individualised, 
transdiagnostic risk calculator, which allows for non-linearity in the association 
between age and risk of psychosis onset may offer a modestly improved 
prognostic performance. This calculator may support an improved detection of 
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individuals at risk of developing psychosis in secondary mental health care, in 
particular for the young populations.  
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Figure 1. Core clinical and research components for an effective prevention of psychosis. 
From11. 
 
Detection of at 
risk individuals
Prognosis of 
outcomes
Preventive 
Treatment
Page  24 
Table 1. Sociodemographic characteristics of study population, including the derivation and validation dataset, from 7. 
    
Study population 
(n= 91199)(a) 
Derivation dataset 
(n=33820) 
Validation dataset 
(n=54716) 
Validation vs 
Derivation  
    Mean SD Mean SD Mean SD t P 
Age (years)(a) 32.97 18.63 34.4 18.92 31.98 18.54 18.73 <0.001 
    Count % Count % 
Coun
t % X2 P 
Gender       13.37 <0.001 
 Male 46404 50.88 17303 48.81 
2730
2 49.90   
 Female 44761 49.08 16507 51.16 
2739
8 50.07   
 Missing 34 0.04 10 0.03 16 0.03   
Ethnicity       50.21 <0.001 
 Black 14327 15.71 6879 20.34 7023 12.84   
 White 55679 61.05 18627 55.08 
3539
2 64.68   
 Asian 3830 4.20 1129 3.34 2608 4.77   
 Mixed 3319 3.64 1306 3.86 1957 3.58   
 Other 5700 6.25 3466 10.25 2084 3.81   
 Missing 8344 9.15 2413 7.13 5652 10.33   
Index diagnosis       48.20 <0.001 
 CHR-P  368 0.40 314 0.93 50 0.09   
 
Acute and transient psychotic 
disorders 1370 1.50 553 1.64 725 1.33   
 Substance use disorders 14689 16.11 7149 21.14 6507 11.89   
 Bipolar mood disorders 2558 2.80 950 2.81 1526 2.79   
 Non-bipolar mood disorders 15496 16.99 6302 18.63 8841 16.16   
 Anxiety disorders 24770 27.16 8235 24.35 
1596
0 29.17   
 Personality disorders 3562 3.91 1286 3.80 2116 3.87   
 Developmental disorders 5192 5.69 1412 4.18 3706 6.77   
 
Childhood/adolescence onset 
disorders 13984 15.33 4200 12.42 9629 17.60   
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 Physiological syndromes 7053 7.73 2555 7.55 4424 8.09   
 Mental retardation 2157 2.37 864 2.55 1232 2.25   
(a) SLaM boroughs used to define the derivation (Lambeth and Southwark) and validation (any other) datasets: Lambeth and 
Southwark 33820 (37.08%), any others 54716 (60.00%), missing 2663 (2.92%) 
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Figure 2. Cumulative incidence (Kaplan-Meier failure function) for risk of development of 
psychotic disorders with 95%CIs in 91199 patients accessing SLaM during 2008-2015 
stratified across the derivation and validation datasets. 
 
 
Page  27 
Figure 3. Fractional polynomial analysis investigating the non-linear association between 
incidence rate of developing any psychotic disorder in England and age bands, computed on 
meta-analytical data previously published43. 
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Table 2. Statistics for individual predictor variables in the refined multivariable Cox proportional hazards regression 
analysis of risk for psychosis in the derivation dataset and individual predictor variables for the original model.  
  Refined model 
 Original 
model  
Predictor  
 β 
Coefficient 
95% CI P 
 
β Coefficient  
Age 1 (years)(a) -469.25780 -
825.02600 
-
113.48970 
0.010  
 
- 
Age 2 (years)(b) 17.97139 -23.87948 59.82225 0.400  - 
Gender  
    
   
Male 0.83976 0.49192 1.18760 <0.00
1 
 .5681779  
Female 1 
   
 1 
Age by gender (male) -0.01887 -0.02756 -0.01018 <0.00
1 
 -.0121931 
Age (years) 0.00186 -0.01290 0.01663 0.805  .0117113 
Ethnicity  
    
   
White 1 
   
 1  
Black 1.05500 0.90909 1.20091 <0.00
1 
 1.037915  
Asian 0.47955 0.16086 0.79824 0.003  .5143438  
Mixed 0.66630 0.30616 1.02643 <0.00
1 
 .6044039  
Other 0.34255 0.12499 0.56010 0.002  .4081036 
Index diagnosis 
    
   
CHR-P 1 
   
 1  
Acute and transient psychotic 
disorders 
0.95508 0.64887 1.26129 <0.00
1 
 .9867204  
Substance use disorders -1.95934 -2.29158 -1.62709 <0.00
1 
 -1.925903  
Bipolar mood disorders -0.15121 -0.49397 0.19154 0.387  -.1754082  
Non-bipolar mood disorders -1.79230 -2.12307 -1.46154 <0.00
1 
 -1.886428  
Anxiety disorders -2.07204 -2.40071 -1.74336 <0.00
1 
 -2.235825  
Personality disorders -1.53795 -1.95208 -1.12381 <0.00
1 
 -1.547794  
Developmental disorders -2.14695 -2.87448 -1.41943 <0.00
1 
 -3.466732  
Childhood/adolescence onset 
disorders 
-2.00792 -2.48912 -1.52672 <0.00
1 
 -3.25382  
Physiological syndromes -2.44130 -2.92062 -1.96197 <0.00
1 
 -2.463145  
Mental retardation -2.40199 -2.96704 -1.83694 <0.00
1 
 -2.450679 
(a)  (b) age1=age-2  
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 (c) age2=age-1  
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Table 3. Performance of the refined risk calculator -including the non-linear effect of 
age- for transdiagnostic prediction of psychosis in secondary mental health care   
Performance measure Derivation   Validation 
  95% CI   95% CI 
Overall         
 Brier 
(a) 0.027    0.018   
 R
2 (mean, 95% CI) 0.771 0.734 0.806  0.743 0.701 0.781 
Discrimination        
 Harrell's C (mean, 95%CI) 0.814 0.800 0.829  0.805 0.790 0.819 
 
Harrell’s C difference with the 
original model (a) 0.014 0.080 0.020  0.0136 0.060 0.021 
Discrimination slope (b) 0.174 0.177 0.168  0.121 0.125 0.118 
Calibration        
 Calibration-in-the-large 0    0.03   
 
Calibration slope (mean, 
95%CI) 1    0.971 0.932 1.011 
a) Harrell’s C in the original model: Derivation 0.80, Validation 0.797; b) at 10-year. 
 
 
